Company Profile
MaxCyte Stock Price, News & Analysis
- Ticker:
- MXCT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United Kingdom and listed in the U
Stock performance
1.11 USD (+3.74%)
Close
Last updated: August 6, 2026
132M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, MXCT closed up 3.74% at $1.11. No new same-company headline was identified in the current news window.
Company overview
Cell Engineering Platform
MaxCyte provides electroporation systems and services used to engineer cells for research, clinical development, and commercial cell therapies.
ExPERT Platform
The ExPERT instruments introduce molecules into cells at laboratory through commercial scale while preserving cell viability and function.
Strategic Platform Licenses
Partners use MaxCyte technology under Strategic Platform License agreements that can generate instrument, consumable, milestone, and commercial revenue.
SeQure Services
SeQure expands the offering into gene-editing assessment and supporting analytical services for cell-therapy developers.
Future catalysts
The main thing to watch at MaxCyte is its latest development priorities. The update that sharpened the story was with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million. That is the part of the story investors will probably keep circling back to.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of MaxCyte (MXCT)?
MaxCyte (MXCT) most recently closed at 1.11 USD, a +3.74% move versus the previous session.
What is the market cap of MaxCyte (MXCT)?
MaxCyte currently has a market capitalization of 132M USD on BioPharmSignal.
What does MaxCyte do?
Cell Engineering Platform MaxCyte provides electroporation systems and services used to engineer cells for research, clinical development, and commercial cell therapies. ExPERT Platform The ExPERT instruments introduce molecules into cells at laboratory through commercial scale while preserving cell viability and function. Strategic Platform...
On which exchange is MXCT stock listed?
MaxCyte (MXCT) is associated with NASDAQ, United Kingdom and listed in the U, Biopharma.
What is Cell?
Cell Engineering Platform MaxCyte provides electroporation systems and services used to engineer cells for research, clinical development, and commercial cell therapies.
Which conditions is MaxCyte targeting with Cell?
Cell Engineering Platform MaxCyte provides electroporation systems and services used to engineer cells for research, clinical development, and commercial cell therapies. ExPERT Platform The ExPERT instruments introduce molecules into cells at laboratory through commercial scale while preserving cell viability and function. Strategic Platform...
How does MaxCyte describe recent progress with Cell?
The main thing to watch at MaxCyte is its latest development priorities. The update that sharpened the story was with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million. That is the part of the story investors will probably keep circling back to.
What is Engineering?
Cell Engineering Platform MaxCyte provides electroporation systems and services used to engineer cells for research, clinical development, and commercial cell therapies.